Drug intelligence / Profile preview

Vivaslim

Development stage: Unknown
Lead developer: Jbklab
Modality: Small Molecules
Administration: Oral

Overview

Vivaslim is an oral dietary supplement developed by JBK Lab under the Cellmed brand, a South Korean company specializing in pharmacy-exclusive nutritional products. Formulated as a capsule, it is primarily marketed for weight management and metabolic wellness. The product typically contains functional plant-based ingredients such as *Garcinia cambogia* extract, which is rich in hydroxycitric acid (HCA). HCA is known to inhibit the enzyme ATP citrate lyase, thereby reducing the conversion of carbohydrates into stored body fat and potentially assisting in appetite control. Vivaslim is positioned as a nutraceutical aid for body fat reduction and general nutritional support within a holistic metabolic health framework.

Brand names: Vivaslim
Other names: 비바슬림 캡슐

Targets

ACLY (ATP-citrate synthase)

Beyond the preview

Go deeper on Vivaslim.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vivaslim.

Explore the full profile